



December 22, 2025

To,  
Listing Operation Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
(Scrip Code: 544644)

To,  
Listing Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G, Bandra Kurla  
Complex, Bandra (E), Mumbai- 400051  
(SYMBOL: CORONA)

Dear Sir / Madam,

**Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Commencement of Commercial Production**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Company has successfully commenced the additional commercial production of tablet(s) / capsule(s) at the Bhayla manufacturing facility (Facility) of the Company. As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%. The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the Facility.

The additional commercial production commenced with effect from Monday, December 22, 2025 at approximately 10:00 a.m.

The additional commercial production will add a significant milestone in the Company's strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility.

The commercialized additional capacity is entirely being funded through internal accruals.

This intimation is also being made available on the website of the Company at [www.coronaremedies.com](http://www.coronaremedies.com)

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya  
Company Secretary and Compliance Officer